Mostrar el registro sencillo del ítem
Risk of severe clinical events after sustained virological response following direct-acting antiviral therapy in HIV and hepatitis C virus coinfected participants
dc.rights.license | open | en_US |
hal.structure.identifier | Bordeaux population health [BPH] | |
dc.contributor.author | CHALOUNI, Mathieu | |
hal.structure.identifier | Bordeaux population health [BPH] | |
dc.contributor.author | WITTKOP, Linda | |
dc.contributor.author | BANI-SADR, Firouze | |
dc.contributor.author | LACOMBE, Karine | |
hal.structure.identifier | Bordeaux population health [BPH] | |
dc.contributor.author | ESTERLE, Laure | |
hal.structure.identifier | Bordeaux population health [BPH] | |
dc.contributor.author | GILBERT, Camille | |
dc.contributor.author | MIAILHES, Patrick | |
dc.contributor.author | ZUCMAN, David | |
dc.contributor.author | VALANTIN, Marc Antoine | |
dc.contributor.author | BREGIGEON-RONOT, Sylvie | |
hal.structure.identifier | Bordeaux population health [BPH] | |
dc.contributor.author | MORLAT, Philippe | |
dc.contributor.author | BILLAUD, Eric | |
dc.contributor.author | PIROTH, Lionel | |
dc.contributor.author | NAQVI, Alissa | |
dc.contributor.author | SOGNI, Philippe | |
dc.contributor.author | SALMON, Dominique | |
dc.contributor.author | GROUP, Anrs Co Hepavih Cohort Study | |
dc.date.accessioned | 2021-08-27T08:47:27Z | |
dc.date.available | 2021-08-27T08:47:27Z | |
dc.date.issued | 2021-07-01 | |
dc.identifier.issn | 1464-2662 | en_US |
dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/110228 | |
dc.description.abstractEn | OBJECTIVES: Sustained virological response (SVR) decreases the risk of hepatitis C virus (HCV)-related events. Nevertheless, a substantial risk of events persists. We estimated incidences and identified factors associated with severe clinical events after SVR following treatment with a direct-acting antiviral (DAA) in HIV/HCV-coinfected patients. METHODS: Participants from the ANRS CO13 HEPAVIH were included if they reached SVR. Incidence rates of overall mortality, liver-related events, AIDS-defining events, ischaemic events and non-liver non-AIDS-defining cancers (NLNA) were estimated. Factors associated with the risk of those events were identified using Poisson models adjusted on age at SVR and sex. RESULTS: In all, 775 participants were included. Incidence rates (95% confidence interval) of liver-related events, overall mortality, AIDS-defining events, ischaemic events and NLNA cancers per 1000 person-years were 5.9 (3.3-10.3), 22.2 (16.8-29.5), 0.6 (0.1-4.5), 7.3 (4.4-12.2) and 13.7 (9.4-20.0), respectively. For all events, incidence rates were higher in cirrhotic than in non-cirrhotic participants. Cirrhosis, liver stiffness and CD4 count were associated with liver-related events. Factors associated with overall mortality were age, cirrhosis, liver stiffness and gamma-glutamyl transferase (GGT). For ischaemic events and NLNA cancers, associated factors were total cholesterol and CD4 count, respectively. CONCLUSIONS: After SVR following a DAA treatment, liver-related and AIDS-defining events were observed less frequently than NLNA cancers. Severity of liver disease was associated with the risk of liver-related events and of overall mortality but not with ischaemic events and NLNA cancers. Factors reflecting HIV infection were associated with NLNA cancers and liver-related events. | |
dc.language.iso | EN | en_US |
dc.subject.en | DAA treatment | |
dc.subject.en | HCV coinfection | |
dc.subject.en | HIV | |
dc.subject.en | Mortality | |
dc.subject.en | Morbidity | |
dc.subject.en | SVR | |
dc.title.en | Risk of severe clinical events after sustained virological response following direct-acting antiviral therapy in HIV and hepatitis C virus coinfected participants | |
dc.type | Article de revue | en_US |
dc.identifier.doi | 10.1111/hiv.13127 | en_US |
dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
dc.identifier.pubmed | 34212476 | en_US |
bordeaux.journal | HIV Medicine | en_US |
bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
bordeaux.institution | Université de Bordeaux | en_US |
bordeaux.institution | INSERM | en_US |
bordeaux.team | ANRS CO13 HEPAVIH | en_US |
bordeaux.team | MORPH3Eus | en_US |
bordeaux.peerReviewed | oui | en_US |
bordeaux.inpress | non | en_US |
hal.identifier | hal-03327400 | |
hal.version | 1 | |
hal.date.transferred | 2021-08-27T08:47:32Z | |
hal.export | true | |
dc.rights.cc | Pas de Licence CC | en_US |
bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=HIV%20Medicine&rft.date=2021-07-01&rft.eissn=1464-2662&rft.issn=1464-2662&rft.au=CHALOUNI,%20Mathieu&WITTKOP,%20Linda&BANI-SADR,%20Firouze&LACOMBE,%20Karine&ESTERLE,%20Laure&rft.genre=article |
Archivos en el ítem
Archivos | Tamaño | Formato | Ver |
---|---|---|---|
No hay archivos asociados a este ítem. |